![]() |
![]() | ![]() |
We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
![]()
JP Morgan brought Nitinol public in September. NMTI issued 3,000,000 shares. The 3,000,000 shares sold for between 11 to 11 7/8, infusing the corporation with cash. On 10/22/96, Jefferies & Co. Inc. initiated coverage of NMTL with a "buy." On 11/20/96, the FDA cleared NMTI's Simon Nitinol Filter, "a thermal shape-memory nitinol vena cava filter designed to prevent pulmonary embolisms." This is the FDA release article: Wednesday November 20 11:08 AM EDT Nitinol Medical Technologies Receives FDA Approval for Subclavian Implantation of its Simon Nitinol Filter Company Continues to Offer Largest Number of Delivery Options to a $53 Million Worldwide Market BOSTON, Nov. 20 /PRNewswire/ -- NITINOL MED today announced that it has received 510(k) clearance from the Food and Drug Administration ("FDA") to market its Simon Nitinol Filter ("SNF) for implantation through the subclavian vein in the shoulder. The patented SNF, which received FDA approval in 1990, is a thermal shape-memory nitinol vena cava filter designed to prevent pulmonary embolisms. The approval of this additional access route provides increased opportunity for physicians to adapt their existing implantation techniques to individual patient conditions and anatomies. With this approval, Nitinol Medical continues to provide the widest variety of delivery options (leg, neck, arm and shoulder) for any vena cava filter currently on the market. A pulmonary embolism occurs when a blood clot lodges in the vessels supplying blood to the lungs -- a condition which results in approximately 125,000 to 150,000 deaths annually in the U.S. and represented a $53 million worldwide market in 1995. Nitinol's SNF is implanted using the Company's patented, catheter-based delivery systems in a minimally invasive procedure. The SNF is distributed worldwide by C.R. Bard, Inc., a leader in sales of minimally invasive medical devices. Thomas M. Tully, President & CEO of Nitinol Medical Technologies, Inc., stated, "The clearance of the SNF for delivery through the subclavian vein provides our customers with increased flexibility in adapting the implantation of the device to each patient. No other currently available vena cava filter provides such a wide range of access options." Nitinol Medical Technologies, Inc. designs, develops, and markets innovative medical devices that utilize advanced materials and are delivered by minimally invasive procedures. The Company's products are designed to offer alternative approaches to existing complex treatments, thereby reducing patient trauma, shortening procedure, hospitalization and recovery times, and lowering overall treatment costs. The Company's patented medical devices include self-expanding stents, vena cava filters and septal repair devices. To receive Nitinol's latest news release and other corporate documents via FAX -- no cost -- please dial 1-800-PRO-INFO. Enter Nitinol's ticker-NMTI. | ||||||||||||||
|
Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
© 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |